This review analyses the most recent evidence on the efficacy and safety of venetoclax in patients with NPM1-mutated AML, exploring the biological mechanisms underlying sensitivity, post-remission strategies, and therapeutic discontinuation options. The gene discussed is NPM1; the disease is acute myeloid leukemia.